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INTRODUCTIOIN
Tumor invasion and metastasis are responsible for
the progression ofmalignant diseases. These processes
are facilitated by the up-regulation of various types
of proteinases, which induce the escape of cancer cells
from the primary site, breakingdownconnectivebarriers
of the extracellular matrix and basement membrane
(1, 2). In addition to metallo and serine proteinases,
such as MMP-1 or MMP-9 well known to be secreted
outside cells, there is increasing evidence that lysoso-
mal proteinase, cathepsin B, L and D, may also play
an important role in the development and progression
of malignant tumors (3-6).
Cathepsins B, L andD are lysosomal cysteine andas-
partic proteinases, distributed in almost all mammalian
cells. They undergo post-translational modification
of mannose-6 - phosphate residues and are translocated
to lysosomal vesicles via the receptor, which is the
main pathway of intracellular protein turnover (7). The
overexpression of cathepsin D (Cath-D) in aggressive
cancer is observed in breast cancer and prostate cancer,
and is associated with a poor prognosis (4, 8 -10). The
expression of this proteinase is regulated by estrogens
in breast cancer cells throughanon-consensual estrogen-
responsive element (11, 12). In somecancer cells,cathep-
sins B (Cath-B) and L (Cath-L) are either secreted
or associated with the plasma membrane (13-15) and
degrade the extracellularmatrix during tumorprogres-
sion. Their activities are regulated by endogenous in-
hibitors, cystatins A and B (Cys. A, Cys. B), and cys-
tatin C. The imbalancebetweenproteases and inhibitors
is also an important factor in deciding if the cancer is
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malignant (16).
The purpose of this review is to provide an overview
of various new roles of cathepsins in cancer, consid-
ering their potency as a therapeutic target.
CATH-D IN CANCER
Cath-D has mitogenic activity
In breast tumors, Cath-D has been suggested to act
as a mitogen, promoting tumor growth through the
enzymatically inactive pro-peptide (17). The exogenous
addition of Cath-D inMCF-7 breast cancer cells showed
mitogenic activity (18). Glondu and colleagues reported
that the down-regulation of Cath-D expression by an-
tisense gene transfer inhibitedMatrigel outgrowthand
experimental lung metastasis in human MDA-MB-231
breast cancer cells (19). Cath-D is indicated to bemore
essential for tumor growth than for extracellularmatrix
invasion because the effect of Cath-D on cancer cell
proliferation and tumor angiogenesis is independent
of its proteolytic activity. Wild-type Cath-D and its mu-
tant were expressed in 3Y1-Ad 12 rat tumor cells (21).
Wild-type Cath-D, as well as its mutated form lacking
proteolytic activity, stimulated tumor growth. However,
only the wild type inhibited tumor apoptosis, whereas
the inactive formdidnot.Therefore,Cath-Dmight provide
some protection against tumor apoptosis by proteolysis
(19, 20). A synthetic peptide of the precursor domain
of Cath-D showed nomitogenic effect, suggesting that
a receptor of the pro-fragment was not involved. Fur-
thermore, the mitogenic activity of Cath-D was not
blocked by inhibiting the interaction of pro-cath-D
with mannose-6-phosphate receptors (21). An excess
of Man-6-P partially inhibited pro-cath-D binding and
endocytosis, indicating the presence of a Man-6-P in-
dependent receptor for endocytosis that might be re-
lated to Cath-Dmitogenic activity. These results suggest
that Cath-D acts as a protein ligand interacting with
a mitogenic receptor. However the mechanism of mi-
togenic activity is still unclear.
Cath-D attenuates anti-tumoral immune response
Purified Cath-D, as well as culture supernatants from
the human breast carcinoma cell lines, MCF-7 and T
47D, selectively digests macrophage inflammatory
protein (MIP)-1α, MIP-1β, and secondary lymphoid-
tissue chemokine (SLC) (Table 1)(22). The proteolytic
activity was most efficient at pH 4.0 and could not be
detected at a pH greater than 5.5. Such an acidic con-
dition may be rare in the extracellular environment
of normal tissues. However, it is well known that the
extracellular pH of tumors is acidic (23). Breast cancer
cells and macrophages within malignant tissue have
high potential to release protons into the extracel-
lular milieu through the proton pump of vacuolar H+-
ATPase at the plasma membrane (24). V-ATPase is
involved in tumor cell invasion (25). Sennoune and
colleagues revealed that V-ATPase was located at the
plasma membrane of human breast cancer cells and
its activity was greater in highly metastatic cells than
in slightly metastatic cells (26). V-ATPase inhibitors
attenuated the invasion or migration in highlymetas-
tatic cells.
MIP-1α and MIP-1β, which are targets of Cat-D di-
gestion, are implicated in the migration of immature
dendritic cells (DCs) that express the CC chemokine
receptor (CCR)1[receptor of RANTES (regulated upon
activation, normal T cell expressed and secreted) and
MIP-1 α] and CCR5[receptor of RANTES and MIP-1
α/β] in tumor tissues (27). Furthermore, immature
DCs mature and up-regulate the expression of the SLC
receptor CCR7 after exposure to neoplastic cells or
tumor stroma (28), and initiate a tumoricidal immune
response at the primary sites (29). Antigen-loadedma-
ture DCs can then promote an anti-tumor effect by
migrating to secondary lymphoid organs (30). AsWolf
and colleagues (22) hypothesized, the cleavage of SLC
by Cath-D within primary tumor sites may interfere
with the migration of mature DCs to secondary lym-
phoid organs, representing an escape mechanism of
the anti-tumoral immune response. These data suggest
that Cath-D attenuates the anti-tumoral immune re-
sponse by degradation of the chemokines that acti-
vate and migrate DCs (Fig.1). Several chemokines,
not cleaved by Cath-D (such as RANTES [CCL 5],
Table 1. Chemokine Processing by Cathepsin D
(Respective Receptors in Brackets)




IL-6, GCP-2 (CXCR 1,CXCR 2)
Mig, IP-10, I-TAC (CXCR3)
SDF-1(CXCR4)
BCA-1(CXCR5)








(Wolf et al ., 2003)
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MCP-1 [CCL2], SDF-1 [stromal cell-derived factor-1],
and IL-8), are highly expressed in breast cancers (31-
34). SDF-1 is thought to promote themotility of cancer
cells and regulates the directional migration of breast
cancer cells to sites ofmetastasis (35). The chemokine-
proteinase network may regulate cancer progression
in the tumoral extracellular microenvironment.
EXPRESSION OF CATHS-B AND L PAR-
TICIPATES IN MALIGNANCY
Recently, evidences have shown that the activity of
Cath-B and L increases in breast cancer (5, 36, 37), pros-
tate cancer (38) and in early stagegastric carcinoma (39).
Cath-B and L were shown to bemarkers for malignant
breast and prostate tumorsandwere suggestedasuseful
prognostic factors for disease relapse, because this ex-
pression correlated with the invasiveness of breast and
prostate carcinomas (38, 40-42). The enzyme activity
increased inhighly tumorigenic lines compared topoorly
tumorigenic lines.
IMBALANCE BETWEEN CATHS AND INHIBITORS
Cathepsin activity and cysteine proteinase inhibitors
are thought to play an important role in the processes
of tumor invasion and metastasis (43), and the imbal-
ance between them causes invasion and metastasis in
cancer cells (Fig.2)(16).
Significantly reduced levels of cysteine proteinase
inhibitor were observed in malignant prostate tissue
samples (38) and prostate (44) and breast (42) tumor
cell lines. Stefin A (StA) protein decreased with inva-
siveness and reported tumorigenicity, andCys. B pro-
tein was significantly lower in allMDA-MB lines com-
pared with the least invasive and tumorigenic MCF7
line (42). The imbalance contributes to thedevelopment
of a malignant cell phenotype (3). Prostate carcinoma
with an aggressive clone had a greater ratio of Cath-B
to Cys. A (45). Less aggressive cloneshada lower ratio.
Sinha and colleagues showed a significant positive
association between the ratio of Cath-B to Cys. A a
nd the incidence of pelvic lymphnode metastasis.
Cath-B and L activity increased significantly in DU
145-conditioned media at high cell density (44). The
ratio of cathepsin activity to cycteine proteinase inhibi-
Fig.1．Cath-D has a dual effect, stimulating tumor cell proliferation and inhibiting dendritic cells (DCs) migration.
Estrogens stimulate cancer cells for the proliferation and expression of Cath-D. Secreted Cath-D promotes tumor
growth autocrinely and digests SLC and MIP-1 α/β. SLC and MIP-1 α/β regulate the migration of dendritic cells
promoting an anti-tumor effect.







   
tors increased in DU 145 and PC3 cell cultures with
increasing density. DU145 and PC3 penetrated the
Matrigel matrix and this invasion increased with in-
creasing cell density. The ability of cystatin-transfected
PC 3 cells to invade theMatrigelwas attenuated com-
pared to non-transfected cells or cells transfected with
the vector alone (46).
INHIBITION OF CATHEPSINS IN CANCER
CELLS
Antisense studies of Cath-B and L
Mohanamandcolleagues transfectedhumanglioblastma
cells SNB19 with a plasmid containing Cath-B cDNA
in antisense orientation (47). Clones expressing an-
tisense Cath-B cDNA exhibited significant reductions
in Cath-B mRNA and enzyme activity. A Matrigel
invasion assay showed that the antisense-transfected
cells hadmarkedly diminished invasiveness compared
with the controls. An intracerebral injection of SNB
19 stable antisense transfectants resulted in reduced
tumor formation in nudemice. Szpaderska and Frank-
fater also transfected human melanoma A375M and
human prostate carcinoma PC3M with a plasmid con-
taining Cath-B cDNA in antisense orientation (48).
These cells produced 40-50% less Cath-B than control
cells and were proportionately less invasive. Similarly,
the inhibition of Cath-L overexpression in murine
myeloma cells by an antisense approach reduced their
tumorigenic potential (49). These cell lines with low
Cath-L activity exhibited a significant reduction of
tumorigenesis in nudemice, when comparedwith con-
trol cells expressing wild-type levels of Cath-L activity.
These results strongly supported the important role
of Cath-B and L in the invasiveness of cancer cells and
suggested cysteine proteinase inhibitors may be good
candidates for cancer therapy.
Inhibitor studies of Cath-B and L
Chicken cystatin, a commonly used natural inhibitor
of cysteine proteinases, effectively suppressed the
invasion of ras-transformed human breast epithelial
cells, MCF-10 A neoT (50). Cystatin had no effect on
cell viability. Recently, various specific inhibitors for
individual cathepsins have been synthesized (51). It
has also been reported that Cath-B and L inhibitors
prevent cancer cell invasion, cancer metastasis and
cancer-induced osteoporosis. CA-074, a specific inhibi-
tor of Cath-B, was developed as the epoxysuccinyl pep-
tides by Katunuma’s group (52-54). Specific inhibitors
for cathepsin L were developed by Katunuma et al .
and Yasuma et al . (55, 56).
CA-074 decreased theMatrigel invasivenessof pros-
tate cancer-cell PC 3M at a concentration of 10 µM
(48) although it had an opposite effect at 1µM.CA-074
equally neutralized extracellular Cath-B activity at 1
and 10 µM, and 1 µM of CA-074 only weakly inhibited
intracellular Cath-B activity. CA-074 Me, a membrane-
permeant pro-inhibitor which converts to CA-074 after
internalization (57), completely abolished intracellular
Cath-B activity and produced a 45-75% inhibition of
invasion (48). Bervar and colleagues also reported that
membrane permeability was very important for a Cath-
B inhibitor to show an inhibitory effect on the invasion
of the human breast cancer cell,MCF10AT(58). These
results suggested that Cath-B had an important intra-
cellular function in matrix degradation and invasion.
On the other hand, E-64, a non-selective cysteine
Fig.2．The imbalance between Caths and cystein protease inhibitors (CPIs) in tumor cells. Overexpression and secretion of
cathepsins induce the invasion and metastasis of tumor cells.
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proteinase inhibitor, reduced invasion but had no effect
on intracellular Cath-B activity(50). E-64 had no effect
on cell motility. One ormorecysteineproteinases, except
cathepsin B, may be involved in matrix degradation.
CLIK-148, a specific Cath-L inhibitor, was evaluated
for protection against bone metastasis of cancer cells
(16). Colon 26 murine carcinoma PMF-15cells were
subcutaneously inoculated over the calvaria of CDF1
mice to induce calvaria adsorption. The calvarial calcium
contents in tumor-bearing calvarias decreased to about
30% of that in normal calvarias, and iv or po administra-
tion of CLIK-148 significantly suppressed the decreases
Fig.3．Inhibitory effect of mouse calvaria bone absorption induced by tumor implantation using CLIK-148. Colon
tumor 26 PMF-15 cells (1×106cells/mice) were subcutaneously inoculated over the calvaria of CDF1 mice on day




) from days 1 to 7. A vehicle was administered orally in the non-
tumor bearing ( ) and tumor-bearing control groups ( ). Pamidronate (

, 5 mg/kg) was administered by
i.v. on days 1, 3, and 5 as a positive control. On day 8, the calcium content of the calvaria was determined spectro-
scopically. Values are the means and SD (n=8).＊＊P ＜0.01 vs. tumor-bearing control by Welch’s t -test.
Fig.4．Suppression by CLIK-148 of distant bone metastasis created by the implantation of human
melanoma A375 cells. A375 cells (1×106 cells/mice) were injected into the left ventricle of a
mouse heart on day 0. CLIK-CLIK-148 (100, 200 mg/kg) was administered from day 7 to 20 (po,
bid), and incadronate (3 mg/kg) was administered on days 7 and 14 (iv) as a positive control. The
values are the means and SD of the area of bone metastasis. ＊＊P＜0.01 vs. tumor-bearing control
by Welch’s t -test.
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in the level of calvarial calcium (Fig. 3)(16). CLIK-148
treatment also reduced the distant bone metastasis
model of human melanoma A375 cells, which were
implanted into the left ventricle of the heart and invaded
via systemic circulation (Fig.4)(16). Bone metastasis
is very common in prostate cancer and is responsible
for the morbidity of this disease (59, 60). The Cath-
L inhibitor has the potential for treatment.
Joyce and colleagues showed that JPM-OEt, an analog
of irreversible Cath binding scaffold E-64 as a broad-
spectrum cysteine proteinase inhibitor (61), had pro-
found effects on tumor growth, invasiveness, and an-
giogenic switching, disrupting both early and late stages
of tumorigenesis in RIP1-Tag2 transgenic mice (6).
They found that the expression and activity of several
Caths were upregulated in the invasive edges of pancre-
atic islet carcinomas during RIP1-Tag2 tumorigenesis.
In contrast, both individual gene knockouts of mem-
bers of the MMP and serine proteinase family (MMP-
2, MMP-9 and uPA) and broad-spectrum MMP inhi-
bition did not affect to the progression of invasive car-
cinomas in this model (62). They propose that Caths
facilitate invasive growth capability, through the pro-
teolysis of E-cadherin. The loss of E-cadherin function
is a determinant of the invasive growth capability in
this transgenic mouse (63).
CONCLUSION
The role of Caths in cancer progression is summa-
rized in Table 2. Cath-D hasmitogenic activity in cancer
cells and reduces the primary immune response in-
hibiting the functions of chemokines. Cath-B works
intracellularly and results in cancer cell in invasion or
matrix degradation. Cath-L has an important role in
extracellular matrix degradation. In cancer tissues,
these Cathsmay act in concert to promotemalignancy
and can therefore be a good target for cancer therapy.
ACKNOWLEDGEMENTS
We thank Drs. Takashi Soda, Yasuo Sugiyama,
Kenichiro Naito and Yoshikazu Ohta (Takeda Phar-
maceutical Company, Ltd.) for their useful advice on
the preparation of this manuscript.
REFERENCES
1. Liotta LA, Rao CN, Wewer UM : Biochemical
interactions of tumor cells with the basement
membrane. Annu Rev Biochem 55 : 1037-1035,
1986
2. Woodhouse EC, Chuaqui RF, Liotta LA : General
mechanisms of metastasis. Cancer 80 : 1529-1537,
1997
3. Kos J, Lah TT : Cysteine proteinases and their
endogenous inhibitors : target proteins for prog-
nosis, diagnosis and therapy in cancer (review).
Oncol Rep 5 : 1349-1346, 1998
4. Foekens JA, LookMP, Bolt-de Vries J,Meijer-van
Gelder ME, van PuttenWL, Klijn JG : Cathepsin-
D in primary breast cancer : prognostic evaluation
involving 2810 patients. Br J Cancer 79 : 300-307,
1999
5. Lah TT, Cercek M, Blejec A, Kos J, Gorodetsky
E, Somers R, Daskal I : Cathepsin B, a prognostic
indicator in lymph node-negative breast carcinoma
patients : comparison with cathepsinD, cathepsin
L, and other clinical indicators. Clin Cancer Res
6 : 578-584, 2000
6. Joyce JA, Baruch A, Chehade K, Meyer-Morse
N, Giraudo E, Tsai FY, Greenbaum DC, Hager
JH, Bogyo M, Hanahan D : Cathepsin cysteine
proteases are effectors of invasive growth and
angiogenesis during multistage tumorigenesis.
Cancer Cell 5 : 443-453, 2004
7. Gabel CA, Goldberg DE, Kornfeld S : Identifica-
tion and characterization of cells deficient in the
mannose 6-phosphate receptor:evidence for an
Table 2. Role of cathepsin D, B and L in tumor
Mitogenic activity
on cancer cells
Proteinase activity Inhibitory effect
Cathepsin D + Degradation of MIP-1α/β, SLC Anti-tumoral immune
response
Cathepsin B ‐









T. Nomura et al. Cathepsins in cancer progression６
alternate pathway for lysosomal enzyme targeting.
Proc Natl Acad Sci USA 80 : 775-779, 1983
8. Rochefort H : Cathepsin D in breast cancer : a
tissue marker associated with metastasis. Eur
J Cancer 28A : 1780-1783, 1992
9. Ferrandina G, Scambia G, Bardelli F, Benedetti
Panici P, Mancuso S, Messori A : Relationship
between cathepsin-D content and disease-free
survival in node-negative breast cancer patients:
a meta-analysis. Br J Cancer 76 : 661-666, 1997
10. Cherry JP,Mordente JA,ChapmanJR,Choudhury
MS, Tazaki H, Mallouh C, Konno S : Analysis of
cathepsin D forms and their clinical implications
in human prostate cancer. J Urol 160 (6 Pt 1) :
2223-2228, 1998
11. Rochefort H, Cavailles V, Augereau P, Capony
F, Maudelonde T, Touitou I, Garcia M : Over-
expression and hormonal regulation of pro-
cathepsin D inmammary and endometrial cancer.
J Steroid Biochem 34 : 177-182, 1989
12. Cavailles V, Augereau P, Rochefort H : Cathepsin
D gene is controlled by a mixed promoter, and
estrogens stimulate only TATA-dependent tran-
scription in breast cancer cells. Proc Natl Acad
Sci USA 90 : 203-207, 1993
13. Sloane BF, Rozhin J, Hatfield JS, Crissman JD,
Honn KV : Plasmamembrane-associatedcysteine
proteinases in human and animal tumors. Exp
Cell Biol 55 : 209-224, 1987
14. Denhardt DT, Greenberg AH, Egan SE, Hamilton
RT, Wright JA : Cysteine proteinase cathepsin L
expression correlates closely with the metastatic
potential of H-ras-transformedmurine fibroblasts.
Oncogene 2 : 55-59, 1987
15. Qian F, Bajkowski AS, SteinerDF,ChanSJ,Frankfater
A : Expression of five cathepsins inmurinemela-
nomas of varying metastatic potential and normal
tissues. Cancer Res 49 : 4870-4875, 1989
16. Katunuma N, Tsuge H, Nukatsuka M, Asao T,
Fukushima M : Structure-based design of specific
cathepsin inhibitors and their application to pro-
tection of bone metastases of cancer cells. Arch
Biochem Biophys 397 : 305-311, 2002
17. Vetvicka V, Vetvickova J, Fusek M : Anti-human
procathepsin D activation peptide antibodies
inhibit breast cancer development. Breast Cancer
Res Treat 57 : 261-269, 1999
18. Fusek M and Vetvicka V:Mitogenic function of
human procathepsinD : the role of the propeptide.
Biochem J 303(Pt 3) : 775-780, 1994
19. Glondu M, Liaudet-Coopman E, Derocq D, Platet
N, Rochefort H, Garcia M: Down-regulation of
cathepsin-D expression by antisense gene transfer
inhibits tumor growth and experimental lungme-
tastasis of human breast cancer cells. Oncogene
21 : 5127-5134, 2002
20. Berchem G, Glondu M, Gleizes M, Brouillet
JP, Vignon F, Garcia M, Liaudet-Coopman E :
Cathepsin-D affects multiple tumor progression
steps in vivo : proliferation, angiogenesis and
apoptosis. Oncogene 21 : 5951-5955, 2002
21. Glondu M, Coopman P, Laurent-Matha V, Garcia
M, Rochefort H, Liaudet-Coopman E : A mutated
cathepsin-D devoid of its catalytic activity stimu-
lates the growth of cancer cells. Oncogene20 :
6920-6929, 2001
22. Wolf M, Clark-Lewis I, Buri C, LangenH, LisM,
Mazzucchelli L : CathepsinD specifically cleaves
the chemokinesmacrophage inflammatory protein-
1 alpha, macrophage inflammatory protein-1 beta,
and SLC that are expressed in human breast
cancer. Am J Pathol 162 : 1183-1190, 2003
23. Griffiths JR : Are cancer cells acidic? Br J Cancer
64 : 425-427, 1991
24. Montcourrier P, Silver I, Farnoud R, Bird I,
Rochefort H : Breast cancer cells have a high
capacity to acidify extracellular milieu by a dual
mechanism. Clin Exp Metastasis 15 : 382-392,
1997
25. Kubota S, Seyama Y : Overexpression of vacuolar
ATPase 16-kDa subunit in 10T1/2 fibroblasts
enhances invasion with concomitant induction
of matrix metalloproteinase-2. Biochem Biophys
Res Commun 278 : 390-394, 2000
26. Sennoune SR, Bakunts K, Martinez GM, Chua-
Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan
R : Vacuolar H+ -ATPase inHumanBreast Cancer
Cells with Distinct Metastatic Potential : Distri-
bution and Functional Activity. Am J Physiol
Cell Physiol 286 : C1443-1452, 2004
27. Homey B, Muller A, Zlotnik A : Chemokines :
agents for the immunotherapy of cancer? Nat
Rev Immunol 2 : 175-184, 2002
28. Sallusto F, Schaerli P, Loetscher P, Schaniel C,
Lenig D, Mackay CR, Qin S, Lanzavecchia A :
Rapid and coordinated switch in chemokine re-
ceptor expression during dendritic cell maturation.
Eur J Immunol 28 : 2760-2769, 1998
29. Sozzani S, Allavena P, Vecchi A, Mantovani A :
Chemokines and dendritic cell traffic. J Clin Im-
munol 20 : 151-160, 2000
30. Vicari AP, Caux C, Trinchieri G : Tumour escape
from immune surveillance through dendritic cell
inactivation. Semin Cancer Biol 12 : 33-42, 2002
The Journal of Medical Investigation Vol. 52 February 2005 ７
31. Luboshits G, Shina S, Kaplan O, Engelberg S,
Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar
I, Ben-Baruch A : Elevated expression of the CC
chemokine regulated on activation, normal T cell
expressed and secreted (RANTES) in advanced
breast carcinoma. Cancer Res 59 : 4681-4687, 1999
32. Saji H, Koike M, Yamori T, Saji S, Seiki M,
Matsushima K, Toi M : Significant correlation of
monocyte chemoattractant protein-1 expression
with neovascularization and progression of breast
carcinoma. Cancer 92 : 1085 -1091, 2001
33. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi
K, Koike M, Inadera H, Matsushima K : Signifi-
cance of macrophage chemoattractant protein-
1 in macrophage recruitment, angiogenesis, and
survival in human breast cancer. Clin Cancer
Res 6 : 3282-3289, 2000
34. De Larco JE, Wuertz BR, Rosner KA, Erickson
SA, Gamache DE, Manivel JC, Furcht LT: A po-
tential role for interleukin-8 in themetastatic phe-
notype of breast carcinoma cells. Am J Pathol 158:
639-649, 2001
35. Fernandis AZ, Prasad A, BandH, Klosel R, Ganju
RK : Regulation of CXCR4-mediated chemotaxis
and chemoinvasion of breast cancer cells. Onco-
gene 23 : 157-167, 2004
36. Lah TT, Kos J, Blejec A, Frkovic-GeorgioS,Golouh
R, Vrhovec I, Turk V :TheExpressionofLysosomal
Proteinases and Their Inhibitors in Breast Can-
cer : Possible Relationship to Prognosis of the
Disease. Pathol Oncol Res 3 : 89-99, 1997
37. Levicar N, Kos J, Blejec A, Golouh R, Vrhovec I,
Frkovic-Grazio S, LahTT : Comparison ofpotential
biological markers cathepsin B, cathepsin L, stefin
A and stefin B with urokinase and plasminogen
activator inhibitor-1 and clinicopathological data
of breast carcinoma patients. Cancer Detect Prev
26 : 42-49, 2002
38. Friedrich B, Jung K, Lein M, Turk I, Rudolph B,
Hampel G, Schnorr D, Loening SA : Cathepsins
B, H, L and cysteine protease inhibitors in malig-
nant prostate cell lines, primary cultured prostatic
cells and prostatic tissue. Eur J Cancer 35:138-
144, 1999
39. Dohchin A, Suzuki JI, Seki H,MasutaniM, Shiroto
H, Kawakami Y : Immunostained cathepsins B
and L correlate with depth of invasion and different
metastatic pathways in early stage gastric carci-
noma. Cancer 89 : 482-487, 2000
40. ThomssenC,Oppelt P, Janicke F, UlmK,Harbeck
N, Hofler H, KuhnW,Graeff H, SchmittM : Iden-
tification of low-risk node-negative breast cancer
patients by tumor biological factors PAI-1 and
cathepsin L. Anticancer Res18:2173-2180, 1998
41. Foekens JA, Kos J, Peters HA, Krasovec M,
Look MP, Cimerman N, Meijer-van Gelder ME,
Henzen-Logmans, SC, van Putten,WL, Klijn, JG :
Prognostic significance of cathepsins B and L
in primary human breast cancer. J Clin Oncol
16 : 1013-1021, 1998
42. Zajc I, Sever N, Bervar A, Lah TT: Expression
of cysteine peptidase cathepsin L and its inhibi-
tors stefins A and B in relation to tumorigenicity
of breast cancer cell lines. Cancer Lett 187:185-
190, 2002
43. Schwartz MK : Tissue cathepsins as tumormark-
ers. Clin Chim Acta 237 : 67-78, 1995
44. Colella R, Goodwyn E, Gopal P : Increased cell
density decreases cysteine proteinase inhibitor
activity and increases invasive ability of two pros-
tate tumor cell lines. Cancer Lett 185 : 163-172,
2002
45. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET,
Reddy PK, Ewing SL, Gleason DF : Prediction
of pelvic lymph node metastasis by the ratio of
cathepsin B to stefin A in patients with prostate
carcinoma. Cancer 94 : 3141-3149, 2002
46. Colella R, Casey SF : Decreased activity of cathep-
sins L＋B and decreased invasive ability of PC3
prostate cancer cells. BiotechHistochem78 : 101-
108, 2003
47. MohanamS, Jasti SL, Kondraganti SR,Chandrasekar
N, Lakka SS, Kin Y, Fuller GN, YungAW, Kyritsis
AP, Dinh DH, Olivero WC, Gujrati M, Ali-Osman
F, Rao JS : Down-regulation of cathepsin B ex-
pression impairs the invasive and tumorigenic
potential of human glioblastoma cells. Oncogene
20 : 3665-3673, 2001
48. Szpaderska AM, Frankfater A:An intracellular
form of cathepsin B contributes to invasiveness
in cancer. Cancer Res 61 : 3493-3500, 2001
49. Kirschke H, Eerola R, Hopsu-Havu VK, Bromme
D, Vuorio E : Antisense RNA inhibition of cathep-
sin L expression reduces tumorigenicity of ma-
lignant cells. Eur J Cancer 36 : 787-795, 2000
50. Premzl A, Puizdar V, Zavasnik-Bergant V, Kopitar-
Jerala N, LahTT, KatunumaN, SloaneBF,TurkV,
Kos J : Invasion of ras-transformed breast epithelial
cells depends on the proteolytic activity of cysteine
and aspartic proteinases. Biol Chem382 : 853-857,
2001
51. Saegusa K, Ishimaru N, Yanagi K, Arakaki R,
Ogawa K, Saito I, KatunumaN,HayashiY :Cathep-
sin S inhibitor prevents autoantigen presentation
T. Nomura et al. Cathepsins in cancer progression８
and autoimmunity. J Clin Invest 110 : 361-369,
2002
52. Murata M, Miyashita S, Yokoo C, Tamai M,
Hanada K, Hatayama K, Towatari T, Nikawa
T, Katunuma N : Novel epoxysuccinyl peptides.
Selective inhibitors of cathepsin B, in vitro. FEBS
Lett 280 : 307-310, 1991
53. Towatari T, Nikawa T, Murata M, Yokoo C,
Tamai M, Hanada K, Katunuma N : Novel epox-
ysuccinyl peptides. A selective inhibitor of cathep-
sin B, in vivo . FEBS Lett 280 : 311-315, 1991
54. Katunuma N and Kominami E : Structure, Prop-
erties, Mechanisms, and Assays of Cysteine Pro-
tease inhibitors ; Cystatins and E-64 Derivatives.
Methods in Enzymology 251 : 382-397, 1995
55. Katunuma N, Murata E, Kakegawa H,Matsui A,
Tsuzuki H, Tsuge H, TurkD, TurkV, Fukushima
M, Tada Y, Asao T : Structure based development
of novel specific inhibitors for cathepsin L and
cathepsin S in vitro and in vivo. FEBS Lett 458 :
6-10, 1999
56. Yasuma T,Oi S, ChohN,Nomura T, FuruyamaN,
Nishimura A, Fujisawa Y, Sohda T : Synthesis
of peptide aldehyde derivatives as selective in-
hibitors of human cathepsin L and their inhibi-
tory effect on bone resorption. J Med Chem
41 : 4301-4308, 1998
57. Buttle DJ, Murata M, Knight CG, Barrett AJ :
CA074 methyl ester : a proinhibitor for intra-
cellular cathepsin B. Arch BiochemBiophys 299 :
377-380, 1992
58. Bervar A, Zajc I, Sever N, Katunuma N, Sloane
BF, Lah TT: Invasiveness of transformed human
breast epithelial cell lines is related to cathepsin
B and inhibited by cysteine proteinase inhibitors.
Biol Chem 384 : 447-455, 2003
59. Rubin MA, Putzi M, Mucci N, Smith DC,Wojno
K, Korenchuk S, Pienta KJ : Rapid (“warm”)
autopsy study for procurement ofmetastatic pros-
tate cancer. Clin Cancer Res 6:1038-1045, 2000
60. Bubendorf L, Schopfer A, Wagner U, Sauter G,
Moch H, Willi N, Gasser TC, Mihatsch MJ : Me-
tastatic patterns of prostate cancer : an autopsy
study of 1, 589 patients. Hum Pathol 31:578-583,
2000
61. Meara JP, Rich DH: Mechanistic studies on the
inactivation of papain by epoxysuccinyl inhibi-
tors. J Med Chem 39 : 3357-3366, 1996
62. Coussens LM, Fingleton B, Matrisian LM :
Matrix metalloproteinase inhibitors and cancer :
trials and tribulations. Science 295(5564) :2387-
2392 (Review), 2002
63. Perl AK,Wilgenbus P, Dahl U, SembH,Christofori
G : A causal role for E-cadherin in the transition
from adenoma to carcinoma. Nature 392 : 190-
193, 1998
The Journal of Medical Investigation Vol. 52 February 2005 ９
